| Literature DB >> 33326186 |
Mozhgan Sharifizad1,2, Doreen Schmidl1, René M Werkmeister2, Harald Zeisler3, Reinhard Told1,4, Julia Binder3, Lorenz Küssel3, Gerhard Garhöfer1, Leopold Schmetterer1,2,5,6,7,8,9.
Abstract
PURPOSE: To compare retinal vascular parameters between high-risk and low-risk pregnant women over time during pregnancy.Entities:
Keywords: Clinical Trial Database Number; NCT02340442; biomarkers; flicker stimulation; pregnancy; retinal oximetry; retinal vessels
Mesh:
Year: 2020 PMID: 33326186 PMCID: PMC8519143 DOI: 10.1111/aos.14696
Source DB: PubMed Journal: Acta Ophthalmol ISSN: 1755-375X Impact factor: 3.761
Fig. 1Study flow chart.
Body mass index (BMI), Mean arterial blood pressure (MAP), pulse rate (PR) and intraocular pressure (IOP) in the three patient groups for the time‐points TP 2 (2nd trimester, wks 20–28), TP 3 (3rd trimester, wks 30–34) and PP (1‐ to 5‐day postpartum)
| TP2 | TP3 | PP | p‐value | |
|---|---|---|---|---|
| BMI (kg/m2) | ||||
| Group 1 (low‐risk pregnancy, | 22.7 ± 4.4 | <0.001## | ||
| Group 2 (high‐risk pregnancy, | 29.9 ± 6.3 | |||
| Group 3 (nonpregnant healthy controls, | 21.8 ± 4.1 | |||
| MAP (mmHg) | ||||
| Group 1 (low‐risk pregnancy, | 90 ± 5 | 91 ± 5 | 89 ± 4 | <0.001# |
| Group 2 (high‐risk pregnancy, | 110 ± 8 | 115 ± 9 | 108 ± 8 | |
| Group 3 (nonpregnant healthy controls, | 87 ± 4 | <0.001## | ||
| PR (beats/min) | ||||
| Group 1 (low‐risk pregnancy, | 62 ± 7 | 61 ± 7 | 60 ± 6 | 0.003# |
| Group 2 (high‐risk pregnancy, | 70 ± 9 | 72 ± 10 | 72 ± 9 | |
| Group 3 (nonpregnant healthy controls, | 55 ± 7 | <0.001## | ||
| IOP (mmHg) | ||||
| Group 1 (low‐risk pregnancy, | 15.4 ± 3.2 | 15.1 ± 2.9 | 15.3 ± 3.1 | 0.476# |
| Group 2 (high‐risk pregnancy, | 15.7 ± 3.5 | 15.8 ± 3.6 | 15.9 ± 3.3 | |
| Group 3 (nonpregnant healthy controls, | 15.6 ± 3.0 | 0.736## | ||
A repeated measures ancova model was used to compare Groups 1 and 2 (#), a 3‐way ancova model was used to compare Groups 1, 2 and 3 (##).
Flicker‐induced retinal vasodilation in retinal arteries (FLA) and veins (FLV) in the three patient groups for the time‐points TP 2 (2nd trimester, wks 20–28), TP 3 (3rd trimester, wks 30–34) and PP (1‐ to 5‐day postpartum)
| TP2 | TP3 | PP | p‐value | |
|---|---|---|---|---|
| FLA (%) | ||||
| Group 1 (low‐risk pregnancy, | 5.7 ± 1.7 | 5.5 ± 1.3 | 5.8 ± 1.2 | <0.001# |
| Group 2 (high‐risk pregnancy, | 3.1 ± 2.0 | 1.8 ± 1.5 | 3.4 ± 1.7 | |
| Group 3 (nonpregnant healthy controls, | 6.1 ± 1.5 | <0.001## | ||
| FLV (%) | ||||
| Group 1 (low‐risk pregnancy, | 6.3 ± 1.6 | 5.8 ± 1.5 | 6.2 ± 1.4 | <0.001# |
| Group 2 (high‐risk pregnancy, | 4.0 ± 2.1 | 2.6 ± 1.4 | 3.8 ± 1.9 | |
| Group 3 (nonpregnant healthy controls, | 6.5 ± 1.9 | <0.001## | ||
(#) indicates statistical significance between Groups 1 and 2 using a repeated measures ancova model. (##) indicates statistical significant difference comparing Groups 1, 2 and 3 using 3‐way ancova model.
Retinal vessel diameters (central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), AVR, oxygen saturation in retinal arteries (SartO2) and oxygen saturation in retinal veins (SveinO2) in the three patient groups for the time‐points TP 2 (2nd trimester, wks 20–28), TP 3 (3rd trimester, wks 30–34) and PP (1‐ to 5‐day postpartum)
| TP2 | TP3 | PP | p‐value | |
|---|---|---|---|---|
| CRAE ( | ||||
| Group 1 (low‐risk pregnancy, | 187 ± 19 | 185 ± 17 | 188 ± 20 | <0.001# |
| Group 2 (high‐risk pregnancy, | 161 ± 20 | 152 ± 22 | 158 ± 19 | |
| Group 3 (nonpregnant healthy controls, | 187 ± 17 | <0.001## | ||
| CRVE ( | ||||
| Group 1 (low‐risk pregnancy, | 234 ± 24 | 241 ± 26 | 232 ± 22 | 0.009# |
| Group 2 (high‐risk pregnancy, | 241 ± 27 | 250 ± 30 | 244 ± 28 | |
| Group 3 (nonpregnant healthy controls, | 233 ± 23 | 0.022## | ||
| AVR | ||||
| Group 1 (low‐risk pregnancy, | 0.80 ± 0.11 | 0.77 ± 0.10 | 0.81 ± 0.11 | < 0.001# |
| Group 2 (high‐risk pregnancy, | 0.67 ± 0.13 | 0.61 ± 0.12 | 0.65 ± 0.12 | |
| Group 3 (nonpregnant healthy controls, | 0.81 ± 0.11 | <0.001## | ||
| SartO2 (%) | ||||
| Group 1 (low‐risk pregnancy, | 94 ± 2 | 94 ± 3 | 93 ± 3 | 0.635# |
| Group 2 (high‐risk pregnancy, | 93 ± 2 | 93 ± 2 | 93 ± 2 | |
| Group 3 (nonpregnant healthy controls, | 95 ± 2 | 0.331## | ||
| SveinO2 (%) | ||||
| Group 1 (low‐risk pregnancy, | 64 ± 2 | 65 ± 2 | 64 ± 2 | 0.008# |
| Group 2 (high‐risk pregnancy, | 68 ± 2 | 69 ± 2 | 68 ± 2 | |
| Group 3 (nonpregnant healthy controls, | 64 ± 2 | 0.017## | ||
(#) indicates statistical significance between Groups 1 and 2 using a repeated measures ancova model. (##) indicates statistical significant difference comparing Groups 1, 2 and 3 using 3‐way ancova model.
Results of linear regression analysis in pregnant women at TP 2 (2nd trimester, wks 20–28, group 1 + group 2: n = 54)
| MAP (mmHg) | PR (beats/min) | BMI (kg/m2) | Age (years) | |
|---|---|---|---|---|
| TP2 | ||||
| FLA (%) |
|
|
|
|
|
| p = 0.43 |
| p = 0.89 | |
| FLV (%) |
|
|
|
|
|
| p = 0.77 |
| p = 0.35 | |
| CRAE ( |
|
|
|
|
|
|
|
| p = 0.09 | |
| CRVE ( |
|
|
|
|
| p = 0.43 | p = 0.61 |
| p = 0.28 | |
| AVR |
|
|
|
|
|
| p = 0.38 |
| p = 0.89 | |
| SartO2 (%) |
|
|
|
|
| p = 0.52 | p = 0.35 | p = 0.94 | p = 0.47 | |
| SveinO2 (%) |
|
|
|
|
|
| p = 0.19 | p = 0.10 | p = 0.18 | |
A p‐value < 0.05 was considered as the level of significance (bold values).
Results of the multiple regression model at TP 2 (2nd trimester, wks 20‐28, group 1 + group 2: n = 54)
| Multivariate analysis | ||
|---|---|---|
| Coefficients (95% CI) | p‐value | |
| FLA (%) | ||
| MAP (mmHg) | −1.98 (−1.64,−2.41) | 0.005 |
| BMI (kg/m2) | −2.23 (−1.41,−3.07) | 0.012 |
| FLV (%) | ||
| MAP (mmHg) | −1.63 (−1.21,−2.11) | 0.038 |
| BMI (kg/m2) | −2.46 (−1.67,−3.34) | 0.009 |
| CRAE ( | ||
| MAP (mmHg) | −1.94 (−1.55,−2.48) | <0.001 |
| PR (beats/min) | −1.41 (−0.76.−2.17) | 0.365 |
| BMI (kg/m2) | −2.17 (−1.34,−3.22) | 0.040 |
| CRVE ( | ||
| BMI (kg/m2) | 2.24 (1.56,3.04) | 0.005 |
| AVR | ||
| MAP (mmHg) | −2.08 (−1.54,−2,77) | <0.001 |
| BMI (kg/m2) | −2.87 (−2.02,−4.01) | <0.001 |
| SveinO2 (%) | ||
| MAP (mmHg) | 2.17 (1.74, 2.80) | 0.002 |
Results of linear regression analysis in pregnant women at TP 3 (3rd trimester, wks 30‐34, group 1 + group 2: n = 54)
| MAP (mmHg) | PR (beats/min) | BMI (kg/m2) | Age (years) | |
|---|---|---|---|---|
| TP3 | ||||
| FLA (%) |
|
|
|
|
|
| p = 0.22 |
| p = 0.35 | |
| FLV (%) |
|
|
|
|
|
|
|
| p = 0.61 | |
| CRAE ( |
|
|
|
|
|
| p = 0.11 |
| p = 0.62 | |
| CRVE ( |
|
|
|
|
|
| p = 0.15 |
| p = 0.28 | |
| AVR |
|
|
|
|
|
| p = 0.94 |
| p = 0.67 | |
| SartO2 (%) |
|
|
|
|
| p = 0.31 | p = 0.47 | p = 0.94 | p = 0.47 | |
| SveinO2 (%) |
|
|
|
|
|
| p = 0.08 |
| p = 0.52 | |
A p‐value < 0.05 was considered as the level of significance (bold values).
Results of the multiple regression model at TP 3 (3rd trimester, wks 30‐34, group 1 + group 2: n = 54)
| Multivariate analysis | ||
|---|---|---|
| Coefficients (95%CI) | p‐value | |
| FLA (%) | ||
| MAP (mmHg) | −2.13 (−1.77,−2.57) | <0.001 |
| BMI (kg/m2) | −2.27 (−1.59,−2.85) | 0.005 |
| FLV (%) | ||
| MAP (mmHg) | −1.84 (−1.33,−2.25) | 0.023 |
| PR (beats/min) | −1.45 (−0.91,−2.00) | 0.176 |
| BMI (kg/m2) | −2.53 (−1.75,−3.41) | 0.008 |
| CRAE ( | ||
| MAP (mmHg) | −2.24 (−1.77,−2.66) | <0.001 |
| BMI (kg/m2) | −2.09 (−1.36,−2.84) | 0.031 |
| CRVE ( | ||
| MAP (mmHg) | 2.09 (1.66,2.60) | <0.001 |
| BMI (kg/m2) | 2.40 (1.81,3.41) | <0.001 |
| AVR | ||
| MAP (mmHg) | −2.25 (−1.77,−2,92) | <0.001 |
| BMI (kg/m2) | −2.91 (−2.11,−3.86) | <0.001 |
| SveinO2 (%) | ||
| MAP (mmHg) | 2.26 (1.80, 2.96) | <0.001 |
| BMI (kg/m2) | 1.42 (0.91, 1.93) | 0.088 |